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Abstract Rationale: Flesinoxan is a highly potent and
selective 5-HT1A agonist and appears to be a potentially
interesting neuroendocrine serotonergic probe. Objec-
tives: We assessed hormonal (ACTH, cortisol, prolactin
and growth hormone) and temperature responses to
flesinoxan in normal volunteers. Methods: In a double-
blind placebo-controlled study, single doses of 0.5 mg and
1 mg were injected over 10 min into 12 healthy male
volunteers at 1-week intervals. Temperature and hormon-
al responses were measured at times –30, 0, 15, 30, 60,
90, and 120 min. Results: Flesinoxan induced a significant
and dose-dependent increase in adrenocorticotropic hor-
mone (ACTH), cortisol, prolactin (PRL), growth hormone
(GH) and a decrease in body temperature. Tolerance to
flesinoxan was excellent. Conclusions: These results
showed the role of 5-HT1A mechanisms in the PRL,
ACTH, cortisol, GH, and temperature responses to
flesinoxan. In the present study, flesinoxan appears a
very promising serotonergic neuroendocrine probe.
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Introduction
Serotonergic abnormalities have been involved in several
major psychiatric disorders. In particular, 5-HT1A recep-
tors could play an important role in the pathophysiology
of depression and anxiety, and in the mechanism of action
of antidepressants (Naughton et al. 2000). Neuroendo-
crine strategy has been widely applied to assess the
sensitivity of 5-HT1A receptors in living conditions by
using various agonists such as buspirone, ipsapirone,
tandospirone, gepirone or flesinoxan. These agents are
able to induce a release of some hormones such as growth
hormone (GH), prolactin (PRL), adrenocorticotropin
(ACTH) or cortisol, and a decrease in body temperature.
Studies with the 5-HT1A receptor partial agonist buspirone
have reported a significant PRL release (Meltzer et al.
1983; Coccaro et al. 1990; Dinan et al. 1990; Anderson
and Cowen 1992; Bridge et al. 2001), but recent data have
shown the importance of dopaminergic effects of the drug
in the induction of PRL release (Bridge et al. 2001).
Stimulation of the hypothalamo-pituitary-adrenal axis
(HPA) by the 5-HT1A agonist ipsapirone has been
demonstrated in several studies (Kahn et al. 1994; Meltzer
and Maes 1995a; Gelfin et al. 1995; Cleare et al. 1998;
Schwartz et al. 1999). Ipsapirone also stimulates the
hypothalamic-GH axis (Lesch et al. 1989; Cleare et al.
1998; Newman et al. 1999; Cleare and Bond 2000), as
does tandospirone (Miller et al. 1990) and gepirone
(Anderson et al. 1990). However, these 5-HT1A com-
pounds are partial agonists that may have agonist or
antagonist activities and most of them are metabolized
into 1-phenylpiperazine (1-PP), an alpha2-adrenoreceptor
antagonist. These confounding factors could explain
different neuroendocrine profiles. In this contex, Seletti
et al. (1995) reported very interesting results by showing
that flesinoxan induced a dose-dependent decrease in
body temperature and an increase in GH, PRL, ACTH and
cortisol plasma levels. The main interest of this study is
that flesinoxan as a 5-HT1A receptor probe tends to avoid
several methodological problems. Flesinoxan is a potent
and selective 5-HT1A agonist, surpassing buspirone,
gepirone and ipsapirone in receptor affinity (Olivier et
al. 1991). Evidence from several functional models
indicate that flesinoxan behaves as a full agonist at the
5-HT1A receptor, both pre- and postsynaptically (Hadrava
et al. 1995). In rats, flesinoxan increases prolactin levels
at low doses and is able to induce a hypothermic response
comparable to that of 8-hydroxy-2-(di-n-propylamino)ter-
tralin (8-OH-DPAT) (Cryan et al. 1999). In humans, after
oral intake, the distribution half-life of flesinoxan is about
2 h and its elimination half-life is about 9 h. Moreover, in
contrast to most azapirones, flesinoxan is not metabolized
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into 1-phenylpiperazine (1-PP), and is available for
intravenous use. This later point is particularly interesting
since injectable tests appear to be much more reliable and
can be performed in a much shorter time, with an
associated decrease in the influence of confounding
factors, such as stress, fasting, or intake of meals. To
date, there have been no safety problems with flesinoxan,
and the drug has been well tolerated.
In this context, the purpose of the study was to validate
a “flesinoxan test” in normal volunteers by showing a
reliable and dose-dependent release of different hormones
and decrease of oral temperature. More specifically, our




Twelve healthy volunteers took part to the study. They were in
good health, as demonstrated by history and clinical examination.
They were free of depressive symptomatology, as demonstrated by
scores less than 6 on the Beck, Carroll, and Hamilton rating scale
for depression. They were also free of personal history of
depression or alcoholism as well as in their first degree relatives.
The protocol was approved by the Ethical Commitee of the
University of Lige, Belgium. Subjects were fully informed of the
purpose of the study and gave their written informed consent.
All normal volunteers were males aged from 22 to 34 years
[mean (SD)=25.9 (3.6)], and with weight ranging from 55 to 87 kg
[mean (SD)=73.8 (10.3)]. The study used a double-blind cross-over
design. In three different sessions, at 1-week intervals, the subjects
received intravenously flesinoxan 0.5 mg, flesinoxan 1 mg, or
placebo. The drugs were diluted in saline to obtain 20 ml/70 kg and
administered in 10 min.
Procedure
After an overnight fast, an indwelling catheter was inserted into a
forearm vein at 8.30 a.m. The first blood sample (t –30) was
collected at 9.00 a.m. and was followed by six blood samplings at
t0, t+15, t30, t60, t90, t120. The beginning of the flesinoxan
injection took place at t0. All samples contained 10 cc of blood.
They were centrifuged within 2 h and serum was immediately
frozen and kept at –18C until analysis.
Hormone assays
GH, prolactin, cortisol, and ACTH were measured by radioimmu-
noassay (RIA), according to previously published methods
(Franchimont 1968; Ansseau et al. 1984). In particular, intra- and
inter-assay coefficients of variation were, respectively, 13.3 and
14.8% for GH (Franchimont 1968); 10.0 and 10.0% for prolactin
(Franchimont 1969); 4.3 and 8.3% for cortisol (Ansseau et al.
1984). All samples were processed in duplicate within the same
assay.
Clinical assessments
After each blood sampling, blood pressure, pulse rate, oral
temperature (sublingual using an electronic thermistor probe), and
sedative and gastro-intestinal side-effects were recorded. Subjects
were also requested to complete the Profile of Mood States scale
(POMS) (McNair et al. 1971). In addition, at the end of the
procedure, sedative and gastro-intestinal side-effects were globally
rated according to a 6-point scale. Modification in vigilance were
scored as follows:0=no change; 1=very slight drowsiness; 2=slight
drowsiness; 3=drowsiness; 4=significant drowsiness; 5:sleep. Di-
gestive reactions were scored as follows:0=no reaction; 1=slight
and transitory nausea; 2=nausea; 3=strong nausea without emesis;
4=emesis; 5=severe emesis.
Data analysis
Hormonal and temperature responses following flesinoxan or
placebo were assessed by two different methods. First, by peak
values following injection and by the areas under the curve (AUC)
situated between injection and the last blood sampling. Both
analyses were performed using absolute values as well as differ-
ences related to basal level (relative values). Since the results of
both methods were very similar, only the area under the curve
relative values (AUCR) will be reported in this paper. Our data
were not normally distributed and a log-transformation did not
normalize the distribution. Therefore, in order to demonstrate a
dose effect, we used Kruskal-Wallis non-parametric test. The
Wilcoxon test was then used for pairwise comparisons between
groups. All values were expressed as means€SD.
Results
Baseline values
Baseline hormonal values were not different between
placebo day, and both flesinoxan days (0.5 or 1 mg/70 kg).
The 3 test days were not different in temperature values as
well as in blood pressure, pulse rate and POMS scores.
Hormonal responses
ACTH
Flesinoxan injection significantly increased ACTH con-
centrations (Fig. 1A): AUCR (pg.min/ml), placebo –
1300€3930, flesinoxan 0.5 mg 635€2550, flesinoxan 1 mg
3628€6484 (Kruskal-Wallis; P<0.003). Wilcoxon analy-
sis showed a significant ACTH response after flesinoxan
0.5 mg (P<0.05), and after flesinoxan 1 mg (P=0.001).
Cortisol
Flesinoxan administration significantly increased cortisol
concentrations (Fig. 1B): AUCR (g.min/l), placebo –
3178€1750, flesinoxan 0.5 mg –2255€3031, flesinoxan
1 mg 3397€4018 (Kruskal-Wallis; P=0.0002). Wilcoxon
analysis showed a significant increase in cortisol concen-
trations after flesinoxan 1 mg (P<0.0001), but not after
flesinoxan 0.5 mg (P=0.37).
Prolactin
Flesinoxan administration significantly altered PRL con-
centrations (Fig. 1C): AUCR (IU.min/ml), placebo –
28
9104€19772, flesinoxan 0.5 mg 1940€5292, flesinoxan
1 mg 25557€17109 (Kruskal-Wallis; P<0.0001). Wilcox-
on analysis showed a significant increase in PRL
concentrations after flesinoxan 1 mg (P<0.0001). Injec-
tion of flesinoxan 0.5 mg already induced a slight but
significant increase in PRL concentrations (P<0.01).
Growth hormone
Flesinoxan administration significantly increased GH
concentrations (Fig. 1D): AUCR (ng.min/ml), placebo –
39€64, flesinoxan 0.5 mg 18€56, flesinoxan 1 mg
175€262 (Kruskal-Wallis; P<0.005). Wilcoxon analysis
showed a significant increase in GH concentrations after
flesinoxan 1 mg (P<0.01), but also after flesinoxan 0.5 mg
(P<0.01).
Temperature responses
Flesinoxan induced a dose-dependent decrease in oral
temperature (Fig. 2): AUCR (min.C), placebo 3.8€13.3,
flesinoxan 0.5 mg –20.0€28.8, flesinoxan 1 mg –
39.0€25.1 (Kruskal-Wallis; P<0.0002). Wilcoxon analy-
sis showed a significant decrease in oral temperature after
flesinoxan 0.5 mg (P<0.003) and after 1 mg (P<0.0001).
Physiological and psychological responses
The injection of flesinoxan did not induce any significant
change in cardiologic parameters such as pulse, systolic
and diastolic blood pressure. In contrast, flesinoxan
induced a statistically significant decrease in POMS
vigilance factor. However, we did not observe any
statistically significant difference between placebo day
and flesinoxan days for gastro-intestinal side effects. In
Fig. 1 Time-dependent effect of flesinoxan (0.5 mg dashed line; 1 mg solid line) and placebo (dotted line) on plasma ACTH (A), cortisol
(B), prolactin (C) and growth hormone (D) concentrations
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fact, only four patients reported slight nausea after
administration of flesinoxan 1 mg.
The high dose of flesinoxan did not induce any
significant effect on POMS tension, confusion, depression
or anxiety factors. In contrast, flesinoxan 1 mg increased
fatigue factor and decreased vigor factor scores.
Discussion
Our results demonstrated a very significant effect of
flesinoxan on neuroendocrine function and body temper-
ature in male healthy volunteers. Indeed, administration
of flesinoxan induced a very significant and dose-
dependent increase in ACTH, cortisol, PRL, GH and a
decrease in oral temperature.
Flesinoxan 1 mg induced a very significant increase in
ACTH and cortisol concentrations which is in line with
several neuroendocrine studies using ipsapirone, gepir-
one, buspirone, fenfluramine or flesinoxan (Lesch et al.
1989; Anderson et al. 1990; Rausch et al. 1990; Maes et
al. 1991; Cowen et al. 1994; Kahn et al. 1994; Meltzer
and Maes 1994a, 1995a; Gelfin et al. 1995; Seletti et al.
1995; Cleare et al. 1998; Schwartz et al. 1999; Rama-
subbu et al. 2000), and more specifically confirm the
results of Seletti et al. (1995) who observed such an
increase in plasma ACTH and cortisol levels with the
high dose (1 mg) of flesinoxan. Our study is unable to
state if the increase in plasma ACTH concentrations is
due to the release of hypothalamic corticotropin releasing
hormone (CRH) or to a direct stimulation of the ante-
hypophysis. However, the identification of 5-HT1A
receptors at the level of several hypothalamic nucleus
(Pazos et al. 1988) suggests that flesinoxan activates 5-
HT1A receptors at the level of the paraventricular nucleus.
Moreover, serotonergic receptors of the ante-hypophysis
are mainly 5-HT2 subtypes. Concerning cortisol, a direct
effect of flesinoxan on adrenal gland is not excluded
(Dinan 1996). However, 5-HT receptors implicated in
cortisol release at the level of the adrenal gland are 5-HT4
receptor subtypes (Delarue et al. 1998) and it is unlikely
to achieve a stimulation of 5-HT4 receptors with
flesinoxan.
The observation of PRL response to flesinoxan is in
accordance with several studies performed in humans and
demonstrating a significant increase in PRL secretion
after administration of buspirone (Meltzer et al. 1983;
Coccaro et al. 1990; Anderson and Cowen 1992) or
gepirone (Anderson et al. 1990). In contrast, most studies
failed to demonstrate an ipsapirone effect on PRL release
which could be related to the fact that ipsapirone is a
partial agonist (Lesch et al. 1989; Kahn et al. 1994).
However, this effect remains controversial. Indeed,
recently, in a placebo-controlled study, Clear et al.
(1998) showed an increase in PRL levels after adminis-
tration of ipsapirone (20 mg) in healthy men. In fact, it
has been suggested that flesinoxan induced PRL response
could require the integrity of both 5-HT1A and 5-HT2
receptors. Meltzer and Maes (1995b) suggested that both
receptors could act on an additive or interactive mode to
obtain maximal PRL effect.
The very significant increase in GH after flesinoxan
completely parallels those reported by Seletti et al. (1995)
and is consistent with studies using other 5-HT1A agonists
such as ipsapirone, gepirone or tandospirone to stimulate
GH response (Lesch et al. 1989; Anderson et al. 1990;
Miller et al. 1990; Cleare et al. 1998; Newman et al. 1999;
Cleare and Bond 2000). This hormonal effect appears to
be mediated through the stimulation of post-synaptic 5-
HT1A receptors (Seletti et al. 1995). Indeed, Seletti et al.
(1995) reported antagonism of the GH response to
flesinoxan by pindolol but not methysergide. The role
of 5-HT1A receptors in GH response to a 5-HT1A agonist
has been observed in other studies. Lesch (1991) demon-
strated the blocking effect of pindolol on GH response to
ipsapirone. An antagonizing action of pindolol has also
been observed with buspirone (Anderson and Cowen
1992).
Flesinoxan-induced hypothermia tends to confirm
results from several animal and human studies assessing
the effect of different 5-HT1A receptor agonists on core
body temperature (Anderson et al. 1990; Lesch et al.
1990; Millan et al. 1993; Young et al. 1993; Kahn et al.
1994; Cleare et al. 1998; Cryan et al. 1999, McAllister-
Williams et al. 2001). More specificaly, our results are in
agreement with those of Seletti et al. (1995), who reported
a dose-related decrease in body temperature after admin-
istration of flesinoxan (7 and 14 g/kg). This hypothermic
effect is probably mediated through the stimulation of 5-
HT1A receptors. Indeed, recently, Cryan et al. (1999)
demonstrated that pretreatment with the selective 5-HT1A
receptor antagonist WAY 100635 blocked hypothermic
response to flesinoxan in rats. Moreover, flesinoxan-
induced hypothermia could be due at least in part to the
stimulation of somatodendritic 5-HT1A receptors (Cowen
2000). In fact, the nature of neuronal mechanisms
involved in the hypothermic effect remains a subject of
Fig. 2 Time-dependent effect of flesinoxan (0.5 mg dashed line;
1 mg solid line) and placebo (dotted line) on oral temperature
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controversy. In the rat, both pre- and postsynaptic
receptors have been implicated (Bill et al. 1991; Millan
et al. 1993; McAllister-Williams et al. 2001), and in the
mouse hypothermic response is mediated via cell body 5-
HT1A receptors (Goodwin et al. 1987; Martin et al. 1992).
However, overall, temperature response to flesinoxan
could be used as a relatively direct, simple and robust
measure of 5-HT1A receptor sensitivity (Cryan et al.
1999).
Most pharmacological agents increasing serotonergic
activity tend to induce side effects such as nausea,
vomiting, dizziness or sedation. Hormonal responses after
administration of a serotonergic agonist could represent
artifacts due to these side effects. In the present study,
flesinoxan-induced side effects were very moderate and
did not explain hormonal responses.
In conclusion, the results of the present study tend to
confirm the validity of flesinoxan as a serotonergic
neuroendocrine probe. Indeed, ACTH, cortisol, PRL, GH
and temperature responses to flesinoxan could be consid-
ered as indirect index of serotonergic activity in living
human. More specifically, flesinoxan-induced hypother-
mia could be used as an easy and not very invasive
technique to measure 5-HT1A receptor sensitivity in living
conditions. The use of thermal response has the advantage
of being a more direct measure than anterior pituitary
hormones whose release is under the control of hypotha-
lamic factors. However, as a research tool, hormonal and
temperature responses to flesinoxan are of a limited
interest. First, currently, it is very difficult to obtain
flesinoxan, particularly for human studies. Second, neu-
roendocrine responses to flesinoxan provide an indirect
index of the sensitivity of 5-HT1A receptors at the
hypothalamic level and we do not know to what extend
a hypothalamically mediated response is informative
regarding the activity of 5-HT1A receptors in other brain
regions.
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